Industry Task Force, FDA Set Timeline For Jumpstarting Third-Party Program
This article was originally published in The Gray Sheet
Executive Summary
A pan-industry/FDA task force will convene in the third week of April to discuss possible improvements to the agency's third party review program.
You may also be interested in...
FDA Enlists CEO Support To Invigorate Slumping Abbreviated 510(k) Program
CEO endorsement is essential to stimulate growth of FDA's abbreviated 510(k) program, staffers and industry representatives maintained at an AdvaMed standards conference in Rockville, Maryland Jan. 9-10.
FDA Enlists CEO Support To Invigorate Slumping Abbreviated 510(k) Program
CEO endorsement is essential to stimulate growth of FDA's abbreviated 510(k) program, staffers and industry representatives maintained at an AdvaMed standards conference in Rockville, Maryland Jan. 9-10.
FDA Pilots Expansion Of Third-Party Review To Devices Without Guidance
Only six of the twelve "accredited persons" have reviewed three or more 510(k) applications under the current third-party program, a requirement for participation in FDA's expanded third-party pilot.